May 31, 2017

소포스부비르, 벨파타스비르, 그리고 복실라프레비르를 이용한 이전 치료를 받은 HCV 감염

Key Points

Key points are not available for this paper at this time.

Abstract

12주 동안 소포스부비르-벨파타스비르-복실라프레비르를 투여받은 환자들은 DAA 요법으로 치료받았으나 실패한 HCV 유전자형 전반에서 지속적인 바이러스 반응률이 높았다. (Gilead Sciences의 자금 지원; POLARIS-1 및 POLARIS-4 ClinicalTrials.gov 번호, NCT02607735 및 NCT02639247.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Marc Bourlière

Inserm

Stuart C. Gordon

Henry Ford Health System

Steven L. Flamm

Rush University Medical Center

Journals

New England Journal of Medicine

Actions

Institutions

University of Washington

University of Pennsylvania

Baylor College of Medicine

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

소포스부비르, 벨파타스비르, 그리고 복실라프레비르를 이용한 이전 치료를 받은 HCV 감염

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study